Anna Cristina Kaltenbach

Anna Cristina Kaltenbach

Auto-generated profile, based on publicly available information

Anna Cristina Kaltenbach

Institute for Cardiovascular Prevention (IPEK), University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2026 in Nature
Verified
Journal Article
Open access
PDF file
DLDaniela Liskiewicz
Daniela Liskiewicz
ANAaron Novikoff
Aaron Novikoff
AKAhmed Khalil
Ahmed Khalil
SASeun Akindehin
Seun Akindehin
JCJonathan E. Campbell
Jonathan E. Campbell
Timo D. MüllerTimo D. Müller
Timo D. Müller
There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R–GIPR co-agonism is effective in the management of obesity and type 2 diabetes 1,2 , and lanifibranor—a nuclear-acting small-molecule triple agonist of PPARα, PPARγ and PPARδ—is in clinical phase 3 trials for the treatment of metabolic dysfunction-associated steatohepatitis 3 . Here, seeking to further improve the metabolic efficacy of GLP-1R–GIPR co-agonism, we report the development of a unimolecular quintuple agonist that combines the body weight-reducing and blood glucose-lowering effects of GLP-1R–GIPR co-agonism with the insulin-sensitizing and anti-inflammatory effects of lanifibranor via its targeted delivery into GLP-1R- and GIPR-expressing cells. In vitro, GLP-1–GIP–lanifibranor is indistinguishable from GLP-1–GIP in relation to incretin receptor signalling and shows equal stimulation of insulin secretion in isolated mouse islets. In vivo, however, GLP-1–GIP–lanifibranor outperforms GLP-1R–GIPR co-agonism and semaglutide, further decreasing body weight, food intake and hyperglycaemia in obese and insulin-resistant mice through synergistic incretin and PPAR action. The metabolic action of GLP-1–GIP–lanifibranor is blunted in mice with genetic or pharmacological inhibition of GLP-1R, GIPR or PPARδ and is absent in DIO double incretin receptor-knockout mice, collectively suggesting that GLP-1–GIP–lanifibranor has substantial therapeutic value in the treatment of obesity and diabetes.

7 July 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
BCBingni Chen
Bingni Chen
APAishvaryaa Prabhu
Aishvaryaa Prabhu
GLGuo Li
Guo Li
AKAnna Kaltenbach
Anna Kaltenbach
YWYong Wang
Yong Wang
SSSabine Steffens
Sabine Steffens
Peripheral cannabinoid CB1 receptor antagonists that lack central nervous system effects are emerging as promising therapies for metabolic disease, yet the role of endothelial CB1 signaling in atherosclerosis remains unclear. Here, we show that endothelial CB1 is expressed in human atherosclerotic plaques, is induced by oscillatory shear stress in atheroprone flow regions, and promotes vascular inflammation, permeability and lipid uptake. Endothelial-specific Cnr1 deletion or peripheral CB1 antagonism in mice attenuates atherosclerosis, reduces endothelial caveolae–dependent low-density lipoprotein uptake by downregulating caveolin-1 and ALK1 expression, and improves metabolic parameters in brown and white adipose tissue and the liver. The anti-atherogenic and metabolic effects are more pronounced in females, which is possibly linked to estrogen signaling. These findings identify endothelial CB1 as a proatherogenic, sex-biased regulator of vascular lipid transport and plaque development and associated metabolic dysfunction.

18 May 2026 in Nature
Verified
Journal Article
Open access
PDF file
DLDaniela Liskiewicz
Daniela Liskiewicz
ANAaron Novikoff
Aaron Novikoff
AKAhmed Khalil
Ahmed Khalil
SASeun Akindehin
Seun Akindehin
JCJonathan E. Campbell
Jonathan E. Campbell
Timo D. MüllerTimo D. Müller
Timo D. Müller

8 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ZMZoe Möller-Ramon
Zoe Möller-Ramon
AKAnna Christina Kaltenbach
Anna Christina Kaltenbach
SPSarah-Lena Puhl
Sarah-Lena Puhl
IKImmanuel Kwok
Immanuel Kwok
FSFlorian Sicklinger
Florian Sicklinger
JDJohan Duchêne
Johan Duchêne
Myocardial infarction (MI) triggers a systemic neutrophil response, yet the roles of distinct neutrophil subsets in cardiac remodeling remain unclear. Studying this requires murine models that accurately mirror human neutrophil dynamics. Here, we show that a minimally invasive intact-chest MI model is more pathophysiologically relevant than the standard open-chest approach for investigating post-MI immune responses. In the open-chest model, surgical trauma disrupts bone marrow homeostasis, releases large numbers of immature neutrophils, and masks MI-specific immune mechanisms. In contrast, the intact-chest model preserves bone marrow integrity and induces only a modest rise in circulating immature neutrophils, closely reflecting MI patient profiles. We further demonstrate that accumulation of immature neutrophils in the infarcted heart exacerbates cardiac dysfunction. Beyond neutrophils, the overall cardiac immune landscape differs markedly between both models. Collectively, our findings establish the intact-chest model as superior for studying post-MI inflammation and reveal immature neutrophils as mediators of adverse cardiac remodeling.

4 September 2025 in Research Square
Verified
Preprint
Open access
PDF file
SSSabine Steffens
Sabine Steffens
BCBingni Chen
Bingni Chen
APAishvaryaa Prabhu
Aishvaryaa Prabhu
GLGuo Li
Guo Li
AKAnna Kaltenbach
Anna Kaltenbach
RPRaquel Guillamat Prats
Raquel Guillamat Prats
Peripherally restricted cannabinoid CB1 receptor antagonists without central side effects hold promise for treating metabolic disorders including diabetes and obesity. In atherosclerosis, the specific effects of peripheral endothelial CB1 signaling remain incompletely understood. Here, we report the expression of the CB1 encoding gene CNR1 in arterial endothelial cells of human plaques. We also show that endothelial CNR1 expression is increased by oscillatory shear stress (OSS) in human aortic endothelial cells (HAoECs) and is higher in atheroprone regions than in atheroresistant regions of murine aortas. Endothelial CB1 deficiency (Cnr1EC-KO) in atheroprone mice resulted in pronounced endothelial phenotypic changes with reduced vascular inflammation and permeability. This led to reduced plaque development with a lower lipid content in female mice, whereas attenuated plaque development, but no changes in plaque lipid content were found in males. Reduced white and brown adipose tissue mass and liver steatosis upon Cnr1EC-KO were observed in both males and females. Ex vivo imaging of female carotid arteries revealed less low density lipoprotein (Dil-LDL) uptake in Cnr1EC-KO. This was accompanied by reduced endothelial caveolin-1 (CAV1) expression, a key structural protein involved in lipid transcytosis, which was only observed in female Cnr1EC-KO mice. In vitro, pharmacological blocking with CB1 antagonist AM281 reproduced the inhibition of CAV1 expression and Dil-LDL uptake in response to atheroprone OSS in HAoECs, which was dependent on cAMP-mediated PKA activation. Conversely, the CB1 agonist ACEA increased Dil-LDL uptake and CAV1 expression in HAoECs. Chronic treatment of atherosclerotic mice with the peripheral CB1 antagonist JD-5037 reduced plaque progression and endothelial CAV1 expression in female mice. Consistent with more pronounced effects in females, HAECs treated with the estrogen receptor ligand estradiol exhibited increased CNR1 and CAV1 expression. These results support a proatherogenic role of endothelial CB1, which appears to be more pronounced in females.